retatrutide triple agonist obesity phase 2 trial Number 1 Top Cardiometabolic Story of 2023: with #retatrutide, a GIP-GLP-1-GCG receptor agonist, resulted in a mean weight reduction of 24.2% after 48 weeks. https://t.co/aED6xEFDI3 Lilly's triple agonist, retatrutide, delivered
Pay in 4 interest-free payments of $7.17 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26










:max_bytes(150000):strip_icc()/VWH-GettyImages-2247616008-f6337b6fe79748e9894463fef7b147d3.jpg)














